← Leaderboards
Shudong Jiang
Dartmouth College
$5,217,728
Attributed
$6,577,674
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,577,674 · 5
By mechanism
R01$5,803,018 · 3
K25$401,261 · 1
R21$373,395 · 1
Top collaborators
- Keith D. Paulsen5 shared
Most similar at Dartmouth College
Same institution · by research overlap
- Keith D. Paulsen$38,192,657
- Paul M Meaney$7,172,923
- John B Weaver$4,666,036
- Steven P Poplack$2,240,285
- Alexander Hartov$2,288,350
Others in their field
Top investigators on “Breast”
- David Heimbrook · Leidos Biomedical Research, Inc.$373,324,203
- Norman Wolmark · Nsabp Foundation, Inc.$299,443,204
- Carol Nesel · Westat$147,274,423
- Richard L Schilsky · University Of Chicago$122,521,723
- Walter John Curran · Thomas Jefferson University$115,541,960
- J Brooks Jackson · Social And Scientific Systems, Inc.$111,373,799
Research focus
BreastImageHemoglobinTissuesCostWaterFundingMalignant Breast NeoplasmResearch PersonnelOxygenTechnologyWomanCollaborationsTomographyOpticsMagnetic Resonance ImagingDesignResponseBaseBreast ImagingTumorPropertyInnovationProcedures
Grant awards (18)
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection$595,711
R01 · FY2025 · EB
3D wearable NIR spectral tomography for early prediction of breast cancerâs residual cancer burden after neoadjuvant chemotherapy$509,797
R01 · FY2025 · CA · contact PI
3D wearable NIR spectral tomography for early prediction of breast cancerâs residual cancer burden after neoadjuvant chemotherapy$549,536
R01 · FY2024 · CA · contact PI
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection$541,513
R01 · FY2022 · EB
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection$497,288
R01 · FY2021 · EB
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection$521,336
R01 · FY2020 · EB
Concurrent Optical Spectroscopy and Breast MRI to Improve Diagnosis without Contrast Injection$564,044
R01 · FY2019 · EB
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography$394,425
R01 · FY2018 · CA · contact PI
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography$394,425
R01 · FY2017 · CA · contact PI
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography$394,425
R01 · FY2016 · CA · contact PI
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography$416,835
R01 · FY2015 · CA · contact PI
Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography$423,683
R01 · FY2014 · CA · contact PI
NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo$173,800
R21 · FY2010 · CA · contact PI
NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo$199,595
R21 · FY2009 · CA · contact PI
Pressure-enhanced near-infrared breast cancer imaging$100,324
K25 · FY2008 · CA · contact PI
Pressure-enhanced near-infrared breast cancer imaging$96,151
K25 · FY2007 · CA · contact PI
Pressure-enhanced near-infrared breast cancer imaging$92,705
K25 · FY2006 · CA · contact PI
Pressure-enhanced near-infrared breast cancer imaging$112,081
K25 · FY2005 · CA